RxDoctor Payments Data

Huy Dang, DPM

Podiatrist · Centralia, WANPI 1801950373

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $45,860 of the $62,802 with a category attached, or 73.0%. Amgen accounts for 89.6% of it on its own, with 18 other manufacturers making up the rest. Among podiatrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,802in general payments, 2019–2025

Across 209 payments — averaging $300.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$56K
  • Smith+Nephew$2K
  • Treace Medical Concepts, Inc.$1K
  • Stryker$1K
  • Fusion Orthopedics USA, LLC$379
  • Organogenesis Inc.$304
  • plus $1K from 13 others

What the payments were for

  • Speaking & faculty fees$45,86073%
  • Travel & lodging$10,71917%
  • Food & beverage$6,20110%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,802 in reported general payments places this provider in the 95th percentile of 134 podiatrist providers in Washington.

See all podiatrist providers in Washington

Medicare billing

Part B allowed, 2024
$2,692,675
Medicare patients
794
Services billed
7,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin75$1,502
Colchicine30$1,238
Febuxostat11$1,195
Allopurinol57$1,090
Ciclopirox28$1,086
Diclofenac Sodium109$1,043
Pregabalin32$1,005
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav75$958
Terbinafine Hcl96$781
Duloxetine Hcl31$615
Doxycycline Monohydrate25$556
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$282
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$272
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$200
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$173

Paid to pharmacies, not to this prescriber.

Other podiatrist in Centralia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →